Israel China Biotechnology (ICB) Ltd (ICB) — Financial Flexibility Index

Latest as of June 2021: -0.26x

Israel China Biotechnology (ICB) Ltd (ICB) has a Financial Flexibility Index of -0.26x as of June 2021. Free cash flow of ILA-1.06 Million (operating CF ILA-1.06 Million minus capex ILA0.00) represents 0% of total liabilities (ILA4.11 Million). Also explore Israel China Biotechnology (ICB) Ltd net asset momentum to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.26x
Free Cash Flow / Total Liabilities

Free Cash Flow

ILA-1.06 Million
Operating CF − Capex

Total Liabilities

ILA4.11 Million
ILA

Capital Expenditures

ILA0.00
ILA

Israel China Biotechnology (ICB) Ltd Financial Flexibility Index (2015–2020)

Historical Financial Flexibility Index trend for Israel China Biotechnology (ICB) Ltd across 6 annual periods. Check how strategically is Israel China Biotechnology (ICB) Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Israel China Biotechnology (ICB) Ltd (2015–2020)

Year-by-year free cash flow to debt coverage for Israel China Biotechnology (ICB) Ltd. For the full company profile including market capitalisation, see market value of Israel China Biotechnology (ICB) Ltd.

Year Flexibility Index Free Cash Flow (ILA) Operating CF Total Liabilities YoY Change
2020 -0.55x ILA-4.33 Million ILA-4.34 Million ILA7.87 Million ▼ -26.2%
2019 -0.44x ILA-4.22 Million ILA-4.22 Million ILA9.68 Million ▲ +75.8%
2018 -1.80x ILA-4.43 Million ILA-4.75 Million ILA2.46 Million ▼ -81.1%
2017 -0.99x ILA-2.85 Million ILA-3.17 Million ILA2.87 Million ▲ +45.7%
2016 -1.83x ILA-3.94 Million ILA-3.94 Million ILA2.15 Million ▼ -16.3%
2015 -1.58x ILA-3.77 Million ILA-3.81 Million ILA2.39 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities